What is ADMA's current stock price?

ADMA (ADMA Biologics, Inc.) is currently trading at $8.24 with a market cap of $1.91B.

What sector is ADMA Biologics, Inc. in?

ADMA Biologics, Inc. (ADMA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ADMA a good stock to buy?

Analysts have a Buy consensus on ADMA with a price target of $21.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ADMA ADMA Biologics, Inc.

Healthcare

$8.24-2.60%ClosedMarket Cap: $1.91B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

15.72

PEG

—

P/B

4.98

P/S

3.75

EV/EBITDA

9.29

DCF Value

$-117.09

FCF Yield

5.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

61.3%

Operating Margin

40.6%

Net Margin

32.4%

ROE

39.0%

ROA

24.9%

ROIC

27.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$114.5M	$45.3M	$—
Q4 null	$139.2M	$49.4M	$—
FY null	$510.2M	$146.9M	$—
Q3 null	$134.2M	$36.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$21.00

Target (Median)

$21.00

Target Range

$18.00 - $24.00

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

MizuhoOutperform

2026-05-07

Canaccord GenuityBuy

2026-05-07

Cantor FitzgeraldNeutral

2026-03-26

Trading Activity

Insider Trades

View All

Grossman Jerrold Bdirector

BuyThu May 14

Grossman Jerrold Bdirector

BuyTue May 12

Kestenberg-Messina Kaitlin M.officer: COO and SVP, Compliance

SellFri Apr 03

Guiheen Lawrence P.director

SellTue Mar 17

Guiheen Lawrence P.director

SellTue Mar 17

Latest News

ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewsWire · Fri May 22

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMAPRNewsWire · Mon May 18

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMAPRNewsWire · Tue May 12

ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman InvestigatingPRNewsWire · Tue Apr 14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.82

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Peers

DYN